OGEN

OGEN 简况

Oragenics, Inc. is a development-stage company that is focused on fighting infectious diseases, including coronaviruses and multidrug-resistant organisms. The Company's lead product, NT-CoV2-1, is an intranasal immunization vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. Its other product candidates include Terra CoV-2 and Antibiotics. Terra CoV-2 is an intramuscular vaccine candidate (plasmid + adjuvant) to provide long-lasting immunity against SARS-CoV-2. Antibiotics is a semi-synthetic analogs of MU1140, which is a member of lantibiotic class of antibiotics. The Company, through its wholly owned subsidiary, Noachis Terra, Inc. (Noachis Terra), is engaged in the research and development of its Terra CoV-2 and NT-CoV2-1 vaccine product candidates. It is also developing semi-synthetic lantibiotic analogs that may be effective against systemic Gram-positive multidrug infections, and analogs that may be effective in treating Gram negative infections.